This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Halozyme Therapeutics

Profile

Halozyme's proprietary ENHANZE® drug delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). Using rHuPH20 enables some biologics to be delivered rapidly in large volumes subcutaneously, which can potentially improve efficiencies for healthcare systems, reduce overall administration time and may reduce the treatment burden for patients.

Contact